If Your Surgery Was Delayed Because of Bupivacaine, You're Not Alone

Bupivacaine is one of the most widely used local anesthetics in the United States. It's used during surgeries, epidurals, dental procedures, and nerve blocks to keep patients comfortable and pain-free. So when hospitals and surgical centers can't get their hands on it, the ripple effects are enormous.

Since mid-2023, Bupivacaine has been on the FDA's official drug shortage list — and in 2026, many formulations remain difficult to find. If your procedure was delayed, rescheduled, or your provider switched to a different anesthetic at the last minute, here's what's going on and what you can do about it.

What Is Bupivacaine?

Bupivacaine (brand names include Marcaine, Sensorcaine, and Exparel) is a long-acting local anesthetic in the amide class. It works by blocking sodium channels in nerve cells, which prevents pain signals from traveling to the brain. It's been a go-to choice for decades because of its long duration of action — often lasting 4 to 8 hours from a single injection.

Healthcare providers use Bupivacaine for a wide range of procedures, including:

• Epidural anesthesia during labor and delivery
• Spinal anesthesia for cesarean sections and lower-body surgeries
• Peripheral nerve blocks for orthopedic procedures
• Dental and oral surgery
• Postoperative pain management

Because it's so versatile and effective, hospitals and surgical centers rely on a steady supply — which makes the current shortage especially disruptive.

Why Is Bupivacaine So Hard to Find?

There isn't one single cause. The Bupivacaine shortage is the result of several overlapping problems:

1. Manufacturing Disruptions

Bupivacaine is a sterile injectable product, which means it must be manufactured under extremely strict conditions. When a production line goes down — whether for maintenance, quality control issues, or equipment failure — it can take months to get back up and running. Several major manufacturers, including Pfizer (which makes Marcaine) and Baxter, have experienced production delays that directly contributed to the shortage.

2. Discontinued Formulations

In early 2023, Baxter discontinued its 0.75% Bupivacaine in 8.25% dextrose 2 mL ampules. When a manufacturer exits the market, the remaining producers can't always absorb the increased demand overnight. This created a domino effect that worsened supply for other concentrations too.

3. Limited Number of Manufacturers

Only a handful of companies produce injectable Bupivacaine in the United States. When the market is concentrated among a few manufacturers, a disruption at even one facility can cause widespread shortages. This is a recurring problem across many generic injectable drugs, not just Bupivacaine.

4. Increased Demand

As the volume of elective surgeries has grown — particularly orthopedic, cosmetic, and outpatient procedures — the demand for Bupivacaine has increased. When supply was already tight, this additional demand made the shortage even worse.

What You Can Do

If you're a patient facing a procedure that requires Bupivacaine, here are some practical steps:

Talk to Your Provider Early

If you have a scheduled surgery or procedure, ask your provider or surgical center about anesthetic availability well in advance. They may be able to source Bupivacaine from alternative suppliers or plan around the shortage.

Ask About Alternatives

Several other local anesthetics can be used in place of Bupivacaine, depending on the procedure. Ropivacaine (Naropin) is the most common substitute — it's in the same drug class and has a similar duration of action, with a slightly lower risk of cardiac side effects. Lidocaine is another option for shorter procedures.

Use Medfinder to Check Availability

If your provider is having trouble sourcing Bupivacaine, Medfinder can help locate facilities and pharmacies that have it in stock. This is especially useful for outpatient surgical centers and clinics that may not have the purchasing power of large hospital systems.

Don't Stockpile

It can be tempting for facilities to order extra when they find supply, but hoarding worsens the shortage for everyone. The FDA and ASHP have encouraged responsible ordering practices to help distribute supply more evenly.

Is the Shortage Getting Better?

The FDA has taken several steps to address the Bupivacaine shortage, including authorizing the temporary importation of Bupivacaine from foreign manufacturers. Some back-ordered formulations have estimated release dates, but timelines have been pushed back multiple times. As of early 2026, the shortage is still listed as active on the ASHP drug shortage database.

For the latest updates on the Bupivacaine shortage, check out our Bupivacaine shortage update for 2026.

Final Thoughts

Bupivacaine is a critical medication that millions of patients depend on every year. The ongoing shortage is frustrating, but understanding why it's happening — and knowing your options — puts you in a better position to work with your healthcare team. Whether that means switching to an alternative anesthetic, timing your procedure strategically, or using tools like Medfinder to track availability, you don't have to navigate this alone.